Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 94 of 272 for:    Betamethasone

Diagnosis of Mycoplasma Pneumoniae Infection With Detection of Specific Antibody-secreting Cells in Community-acquired Pneumonia (CAP) Patients of the Randomised Placebo-controlled Multi-centre Effectiveness Trial of Adjunct Betamethasone Therapy (myKIDS-STEP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04043325
Recruitment Status : Recruiting
First Posted : August 2, 2019
Last Update Posted : August 2, 2019
Sponsor:
Collaborators:
University Children's Hospital Basel
Ostschweizer Kinderspital
Information provided by (Responsible Party):
University Children's Hospital, Zurich

Brief Summary:
To compare presence and kinetics of Mycoplasma pneumoniae (Mp)-specific immunoglobulin (Ig) M antibody-secreting cells (ASCs) with Mp DNA and Mp-specific IgM antibodies in patients with community-acquired pneumonia (CAP) of the KIDS-STEP study.

Condition or disease Intervention/treatment
Community-acquired Pneumonia Diagnostic Test: Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay

Detailed Description:

Community-acquired pneumonia (CAP) is a common serious infection and a leading cause of hospitalisation in children. Knowledge about the underlying pathogen is a major unmet clinical need, particularly in CAP caused by Mycoplasma pneumoniae (Mp). Timely and reliable identification is critical for initiating effective and tailored antimicrobial treatment. However, determining the causative pathogen of childhood CAP is complicated by the low yield of blood cultures and difficulty obtaining specimens from the lower respiratory tract of children. Therefore, clinicians attempt to detect potential pathogens in upper respiratory tract (URT) specimens, knowing that children carry viruses and bacteria in their URT that may or may not be causative for the current pneumonia episode. Consequently, the interpretation of diagnostic tests performed with URT specimens is limited and may lead to unnecessary antimicrobial prescriptions.

The hurdle in differentiating infection from carriage was documented recently for Mp, a frequently reported pathogen underlying CAP in children worldwide (up to 20-40% during epidemics). Current diagnostic tests, including polymerase chain reaction (PCR) of URT specimens or serology, do not reliable differentiate between Mp infection and carriage. Mp is found in the URT in up to 56% of healthy children. These findings challenge recent epidemiological data indicating Mp as the most common bacterial cause of CAP, in up to 23% of hospitalized U.S. children aged 10-17 years. A ≥4-fold increase in IgG antibody levels is still considered the "gold standard" for diagnosing M. pneumoniae infection, but has low sensitivity when e.g. compared with IgM seroconversion and/or a 2-fold IgM increase. In fact, such a definition is also not helpful in acute clinical management, as it requires acute and convalescent sera.

Circulating antigen-specific B cell responses have been investigated in vaccine studies and demonstrated to be more rapid and shorter lived than antibody responses. After exposure, antigen-specific B cells proliferate and differentiate into antibody-secreting cells (ASCs) and memory B cells. ASCs transiently circulate in the peripheral blood in the first days after an antigen encounter. In a recent observational pilot study of children with CAP and healthy controls, we showed that the detection of Mp-specific immunoglobulin (Ig) M ASCs by enzyme-linked immunospot (ELISpot) assay re-classified 15% of PCR-positive and 12% of IgM-seropositive study participants (https://doi.org/10.1164/rccm.201904-0860LE). Thus, the measurement of specific IgM ASCs by ELISpot assay is an innovative, minimally invasive, and rapid test method that optimises diagnosis of Mp CAP in children.

In view of these promising first results, the aim of this study is to establish the diagnosis of Mp infection by the measurement of Mp-specific ASCs by ELISpot in CAP patients enroled in the randomised placebo-controlled multi-centre effectiveness trial of adjunct betamethasone therapy (KIDS-STEP study, Protocol ID: NCT03474991).


Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Diagnosis of Mycoplasma Pneumoniae Infection With Detection of Specific Antibody-secreting Cells in Community-acquired Pneumonia (CAP) Patients of the Randomised Placebo-controlled Multi-centre Effectiveness Trial of Adjunct Betamethasone Therapy (myKIDS-STEP)
Actual Study Start Date : May 20, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia


Intervention Details:
  • Diagnostic Test: Specific antibody-secreting cell (ASC) enzyme-linked immunspot (ELISpot) assay
    Clinical samples (nasopharyngeal swabs and max. 5 ml blood) will be collected from patients enroled in the KIDS-STEP study (NCT03474991; children aged 1-10 years) at enrolment (day 1), at day 3, and at day 28.
    Other Names:
    • Specific enzyme-linked immunosorbent assay (ELISA)
    • Specific polymerase chain reaction (PCR)


Primary Outcome Measures :
  1. Detection of Mp-specific IgM ASCs by ELISpot assay [ Time Frame: Day 1 (at enrolment) ]
    Diagnosis of Mp infection in CAP patients of the KIDS-STEP study with the detection of Mp-specific IgM ASCs by ELISpot assay at enrolment (day 1).


Secondary Outcome Measures :
  1. No detection of Mp-specific IgM ASCs by ELISpot assay [ Time Frame: Day 28 ]
    Longitudinal assessment of levels of Mp-specific IgM ASCs by ELISpot assay.

  2. Detection of Mp-specific DNA by PCR [ Time Frame: Day 28 ]
    Longitudinal assessment of levels of Mp-specific DNA by PCR.

  3. Detection of Mp-specific IgM by ELISA [ Time Frame: Day 28 ]
    Longitudinal assessment of levels of Mp-specific IgM by ELISA.

  4. Detection of specific IgM ASCs against other pathogens by ELISpot assay [ Time Frame: Day 1 ]
    Diagnosis of infection with other respiratory pathogens than Mp in CAP patients of the KIDS-STEP study with the detection of specific IgM ASCs by ELISpot assay at enrolment (day 1).


Biospecimen Retention:   Samples With DNA
Nasopharyngeal specimen, blood sample


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Year to 10 Years   (Child)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Children from age 1 year weighing at least 7 kilograms and up to a body weight of 35 kilograms and age below 10 years admitted to the hospital with signs and symptoms of CAP will be considered potentially eligible for participation.
Criteria

Inclusion Criteria:

  • At least 12 months of age and younger than 10 years of age
  • Body weight between 7 kg and 35 kg
  • Admission to hospital (i.e. assignment of an inpatient case number)
  • Clinical diagnosis of CAP (according to predefined criteria)
  • Parent and/or child (as age-appropriate) willing to accept all possible randomised allocations and to be contacted by telephone weekly up to and including at 4 weeks after randomisation
  • Informed consent form for trial participation signed by parent

Exclusion Criteria:

  • Presence of local chest complications
  • Chronic underlying disease associated with an increased risk of very severe CAP or CAP of unusual aetiology
  • Bilateral wheezing without focal chest signs (most likely to represent respiratory tract infection affecting the medium airways, i.e. not pneumonia)
  • Inability to tolerate oral medication
  • Documented allergy or any other known contraindication to any trial medication
  • Subacute or chronic conditions requiring higher betamethasone equivalent or known primary or secondary adrenal insufficiency
  • Known diabetes mellitus (type 1)
  • Hospitalisation within the last two weeks preceding current admission
  • Exposure to systemic corticosteroids with completion of treatment <2 weeks from enrolment (courses of up to 7 days) or <4 weeks from enrolment (courses of >7 days)
  • Transfer for any reason to a non-participating hospital directly from the paediatric emergency department
  • Parent are unlikely to be able to reliably participate in telephone follow-up because of significant language barriers
  • Participation in another study with investigational drug within the 30 days preceding and during the present study,
  • Previous enrolment into the current study,
  • Enrolment of the investigator, his/her family members, and other dependent persons.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04043325


Contacts
Layout table for location contacts
Contact: Patrick M. Meyer Sauteur, MD PhD +41442667896 patrick.meyer@kispi.uzh.ch

Locations
Layout table for location information
Switzerland
University Children's Hospital Zurich Recruiting
Zürich, Switzerland, 8032
Contact: Patrick M. Meyer Sauteur, MD PhD    +41442667896    patrick.meyer@kispi.uzh.ch   
Contact: Christoph Berger, MD    +41442667840    christoph.berger@kispi.uzh.ch   
Sponsors and Collaborators
University Children's Hospital, Zurich
University Children's Hospital Basel
Ostschweizer Kinderspital

Layout table for additonal information
Responsible Party: University Children's Hospital, Zurich
ClinicalTrials.gov Identifier: NCT04043325     History of Changes
Other Study ID Numbers: 2019-00425
First Posted: August 2, 2019    Key Record Dates
Last Update Posted: August 2, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Betamethasone
Betamethasone Valerate
Betamethasone-17,21-dipropionate
Betamethasone benzoate
Betamethasone sodium phosphate
Pneumonia, Mycoplasma
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Mycoplasma Infections
Mycoplasmatales Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Pneumonia, Bacterial
Antibodies
Immunoglobulins
Immunologic Factors
Physiological Effects of Drugs
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Asthmatic Agents
Respiratory System Agents